Selective Serotonin Reuptake Inhibitor Pharmacokinetics During Pregnancy: Clinical and Research Implications
Pregnancy and associated physiologic changes affect the pharmacokinetics of many medications, including selective serotonin reuptake inhibitors-the first-line pharmacologic interventions for depressive and anxiety disorders. During pregnancy, SSRIs exhibit extensive pharmacokinetic variability that...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Book |
| Published: |
Frontiers Media S.A.,
2022-02-01T00:00:00Z.
|
| Subjects: | |
| Online Access: | Connect to this object online. |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
MARC
| LEADER | 00000 am a22000003u 4500 | ||
|---|---|---|---|
| 001 | doaj_435a8c331c964f57a118d67a2c7cbb4d | ||
| 042 | |a dc | ||
| 100 | 1 | 0 | |a Ethan A. Poweleit |e author |
| 700 | 1 | 0 | |a Ethan A. Poweleit |e author |
| 700 | 1 | 0 | |a Ethan A. Poweleit |e author |
| 700 | 1 | 0 | |a Ethan A. Poweleit |e author |
| 700 | 1 | 0 | |a Margaret A. Cinibulk |e author |
| 700 | 1 | 0 | |a Sarah A. Novotny |e author |
| 700 | 1 | 0 | |a Melissa Wagner-Schuman |e author |
| 700 | 1 | 0 | |a Laura B. Ramsey |e author |
| 700 | 1 | 0 | |a Laura B. Ramsey |e author |
| 700 | 1 | 0 | |a Jeffrey R. Strawn |e author |
| 700 | 1 | 0 | |a Jeffrey R. Strawn |e author |
| 700 | 1 | 0 | |a Jeffrey R. Strawn |e author |
| 245 | 0 | 0 | |a Selective Serotonin Reuptake Inhibitor Pharmacokinetics During Pregnancy: Clinical and Research Implications |
| 260 | |b Frontiers Media S.A., |c 2022-02-01T00:00:00Z. | ||
| 500 | |a 1663-9812 | ||
| 500 | |a 10.3389/fphar.2022.833217 | ||
| 520 | |a Pregnancy and associated physiologic changes affect the pharmacokinetics of many medications, including selective serotonin reuptake inhibitors-the first-line pharmacologic interventions for depressive and anxiety disorders. During pregnancy, SSRIs exhibit extensive pharmacokinetic variability that may influence their tolerability and efficacy. Specifically, compared to non-pregnant women, the activity of cytochrome P450 (CYP) enzymes that metabolize SSRIs drastically changes (e.g., decreased CYP2C19 activity and increased CYP2D6 activity). This perspective examines the impact of pharmacokinetic genes-related to CYP activity on SSRI pharmacokinetics during pregnancy. Through a simulation-based approach, plasma concentrations for SSRIs metabolized primarily by CYP2C19 (e.g., escitalopram) and CYP2D6 (e.g., fluoxetine) are examined and the implications for dosing and future research are discussed. | ||
| 546 | |a EN | ||
| 690 | |a anxiety | ||
| 690 | |a depression | ||
| 690 | |a pharmacokinctics | ||
| 690 | |a pregnancy | ||
| 690 | |a SSRI (selective serotonergic reuptake inhibitors) | ||
| 690 | |a Therapeutics. Pharmacology | ||
| 690 | |a RM1-950 | ||
| 655 | 7 | |a article |2 local | |
| 786 | 0 | |n Frontiers in Pharmacology, Vol 13 (2022) | |
| 787 | 0 | |n https://www.frontiersin.org/articles/10.3389/fphar.2022.833217/full | |
| 787 | 0 | |n https://doaj.org/toc/1663-9812 | |
| 856 | 4 | 1 | |u https://doaj.org/article/435a8c331c964f57a118d67a2c7cbb4d |z Connect to this object online. |